Vivos Therapeutics Acquires The Sleep Center of Nevada

Vivos Therapeutics ( (VVOS) ) just unveiled an update.

On June 10, 2025, Vivos Therapeutics completed the acquisition of The Sleep Center of Nevada, marking its first major acquisition of a sleep testing center. This strategic move is expected to enhance Vivos’ revenue through both diagnostic and consulting services, as well as sales of its patented OSA treatment appliances. The acquisition aligns with Vivos’ pivot to focus on high patient volume centers and higher margin revenues, supported by over $11 million in new financing, including a senior secured loan and a private placement investment. This acquisition provides Vivos direct access to a large patient base, potentially reducing cash burn and moving towards cash flow positivity.

The most recent analyst rating on (VVOS) stock is a Buy with a $6.60 price target. To see the full list of analyst forecasts on Vivos Therapeutics stock, see the VVOS Stock Forecast page.

Spark’s Take on VVOS Stock

According to Spark, TipRanks’ AI Analyst, VVOS is a Neutral.

Vivos Therapeutics faces significant financial and operational challenges, reflected in its weak financial performance and technical indicators. While strategic initiatives and the recent financing for an acquisition offer potential growth, these are overshadowed by ongoing profitability and cash flow issues.

To see Spark’s full report on VVOS stock, click here.

More about Vivos Therapeutics

Vivos Therapeutics, Inc. is a medical technology company that focuses on developing and commercializing innovative diagnostic and treatment methods for sleep wellness and health, particularly for conditions like obstructive sleep apnea (OSA) and snoring. Their proprietary oral appliances are FDA-cleared for treating various severity levels of OSA in adults and children.

Average Trading Volume: 99,861

Technical Sentiment Signal: Sell

Current Market Cap: $13.07M

Find detailed analytics on VVOS stock on TipRanks’ Stock Analysis page.